Neurokinin-3 receptor antagonists in schizophrenia

Bibliography

• GERSPACHER M: Selective and combined neurokinin receptor antagonists. Prog. Med. Chem. (2005) 43:49-103.
   PubMedGoogle Scholar
• GIARDINA GAM, GAGLIARDI S, MARTINELLI M: Antagonists at the neurokinin receptors – recent patent literature. IDrugs (2003) 6:758-772.
   PubMed Web of Science ®Google Scholar
• LECCI A, MAGGI CA: Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin. Ther. Targets (2003) 7:343-362.
   PubMed Web of Science ®Google Scholar
• DUFFY RA: Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin. Emerging Drugs (2004) 9:9-21.
   PubMedGoogle Scholar
• ALBERT JS: Neurokinin antagonists and their potential role in treating depression and other stress disorders. Expert Opin. Ther. Patents (2004) 14:1421-1433.
   Web of Science ®Google Scholar
• RUMSEY WL, KERNS JK: Combined tachykinin NK1, NK2, and NK3 receptor antagonists. Handb. Exp. Pharmacol. (2004) 164:273-296.
   Google Scholar
• PATACCHINI R, MAGGI CA: Tachykinin NK1 receptor antagonists. Handb. Exp. Pharmacol. (2004) 164:173-218.
   Google Scholar
• MAZZONE SB, CANNING BJ: Tachykinin NK3 receptor antagonists. Handb. Exp. Pharmacol. (2004) 164:245-271.
   Google Scholar
• EMONDS-ALT X: Tachykinin NK2 receptor antagonists. Handb. Exp. Pharmacol. (2004) 164:219-244.
   Google Scholar
• DIETL MM, PALACIOS JM: Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: apparent absence of neurokinin-2 and neurokinin-3 binding sites in the human brain. Brain Res. (1991) 539:211-222.
   PubMed Web of Science ®Google Scholar
• MILEUSNIC D, LEE JM, MAGNUSON DJ et al.: Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience (1999) 89:1269-1290.
   PubMed Web of Science ®Google Scholar
• MILEUSNIC D, MAGNUSON DJ, HEJNA MJ et al.: Age and species-dependent differences in the neurokinin B system in rat and human brain. Neurobiol. Aging (1999) 20:19-35.
   PubMed Web of Science ®Google Scholar
• TOONEY PA, AU GG, CHAHL LA: Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci. Lett. (2000) 283:185-188.
   PubMed Web of Science ®Google Scholar
• BUELL G, SCHULZ MF, ARKINSTALL SJ et al.: Molecular characterization, expression and localization of human neurokinin-3 receptor. FEBS Lett. (1992) 299:90-95.
   PubMed Web of Science ®Google Scholar
• RIGBY M, O’DONNELL R, RUPNIAK NMJ: Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J. Comp. Neurology (2005) 490:335-353.
   PubMed Web of Science ®Google Scholar
• SPOOREN W, RIEMER C, MELTZER H: NK3 receptor antagonists: the next generation of antipsychotics? Nat. Rev. Drug Disc. (2005) 4:967-975.
   PubMed Web of Science ®Google Scholar
• MELTZER H, ARVANITIS L, BAUER D, REIN W: Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psych. (2004) 161:975-984.
   PubMed Web of Science ®Google Scholar
• MESNAGE V, HOUETO JL, BONNET AM et al.: Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson’s disease. Clin. Neuropharm. (2004) 27:108-110.
   PubMed Web of Science ®Google Scholar
• KRONENBERG G, BERGER P, TAUBER RF et al.: Randomized, double-blind study of SR142801 (osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry (2005) 38:24-29.
   PubMed Web of Science ®Google Scholar
• EVANGELISTA S: Talnetant GlaxoSmithKline. Curr. Opin. Invest. Drugs (2005) 6:717-721.
   PubMedGoogle Scholar
• SARAU HM, GRISWOLD DE, POTTS W et al.: Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB-223412, a novel, potent and selective neurokinin-3 receptor antagonist. J. Pharm. Exp. Ther. (1997) 281:1303-1311.
   PubMed Web of Science ®Google Scholar
• DUVELLEROY D, PERRIO C, PARISEL O, LASNE M-C: Rapid synthesis of quinoline-4-carboxylic acid derivatives from arylimines and 2-substituted acrylates or acrylamides under indium(III) chloride and microwave activations. Scope and limitations of the reaction. Org. Biomol. Chem. (2005) 3:3794-3804.
   PubMed Web of Science ®Google Scholar
• BENNACEF I, TYMCIU S, DHILLY M et al.: Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies. Bioorg. Med. Chem. (2004) 12:4533-4541.
   PubMed Web of Science ®Google Scholar
• BENNACEF I, TYMCIU S, DHILLY M et al.: Lithiation of functionalized fluoroquinolines: synthesis of dihalo-2-phenylquinoline-4-carboxamides and in vitro evaluation as NK-3 receptor ligands for medical imaging studies. J. Org. Chem. (2004) 69:2622-2625.
   PubMed Web of Science ®Google Scholar
• BLANEY FE, RAVEGLIA LF, ARTICO M et al.: Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. J. Med. Chem. (2001) 44:1675-1689.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, PROIETTO V, STEINBERG R et al.: Biochemical and pharmacological activities of SSR-146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can. J. Physiol. Pharm. (2002) 80:482-488.
   PubMed Web of Science ®Google Scholar
• OWENS AP, HARRISON T, MOSELEY JD et al.: High affinity phenylglycinol-based NK1 receptor antagonists. Bioorg. Med. Chem. Lett. (1998) 8:51-56.
   PubMed Web of Science ®Google Scholar
• ALI MA, BHOGAL N, FINDLAY JBC, FISHWICK CWG: The first de novo-designed antagonists of the human NK2 receptor. J. Med. Chem. (2005) 48:5655-5658.
   PubMed Web of Science ®Google Scholar
• POULSEN A, BJORNHOLM B, GUNDERTOFTE K, POGOZHEVA ID, LILJEFORS T: Pharmacophore and receptor models for neurokinin receptors. J. Comput. Aided Mol. Des. (2004) 17:765-783.
   Web of Science ®Google Scholar
• POULSEN A, LILJEFORS T, GUNDERTOFTE K, BJORNHOLM B: A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes. J. Comput. Aided Mol. Des. (2002) 16:273-286.
   PubMed Web of Science ®Google Scholar
• EVERS A, KLEBE G: Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. (2004) 47:5381-5392.
   PubMed Web of Science ®Google Scholar
• PELLEGRINI M, BREMER AA, ULFERS AL, BOYD ND, MIERKE DF: Molecular characterization of the substance P*neurokinin-1 receptor complex: development of an experimentally based model. J. Biol. Chem. (2001) 276:22862-22867.
   PubMed Web of Science ®Google Scholar
• VEDANI A, BRIEM H, DOBLER M, DOLLINGER H, MCMASTERS DR: Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem. (2000) 43:4416-4427.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI Y, SHANDS EFB, BEUSEN DD, MARSHALL GR: Derivation of a 3-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J. Med. Chem. (1998) 41:3609-3623.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, ROUISSI N, NGUYEN QT et al.: Neurokinin A (NK2) receptor revisited with SR-48968, a potent non-peptide antagonist. Biochem. Biophys. Res. Commun. (1992) 184:1418-1424.
   PubMed Web of Science ®Google Scholar
• HALE JJ, MILLS SG, MACCOSS M et al.: Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. (1998) 41:4607-4614.
   PubMed Web of Science ®Google Scholar
• MCLEAN S, GANONG A, SEYMOUR PA et al.: Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. J. Pharm. Exp. Ther. (1996) 277:900-908.
   PubMed Web of Science ®Google Scholar
• KELLER M, MONTGOMERY S, BALL W et al.: Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psych. (2006) 59:216-223.
   PubMed Web of Science ®Google Scholar